TARGETING GITR ENHANCES HUMAN TUMOUR-INFILTRATING T CELL FUNCTIONALITY IN MISMATCH REPAIR PROFICIENT PRIMARY COLORECTAL CARCINOMA AND LIVER METASTASES

1Yannick Rakké*, 1Lucia Campos Carrascosa, 1Adriaan van Beek, 1Valeria de Ruiter, 1Michael Doukas, 2Susan ter Borg, 3Pascal Doornebosch, 4Maarten Vemaas, 4Erwin van der Harst, 5Peter Paul Coene, 1Dirk Grünhagen, 1Cornelis Verhoef, 1Jan Uzermans, 1Dave Sprengers, 1Jaap Kwekkeboom. 1Erasmus University Medical Center, Rotterdam, Netherlands; 2Pathan BV, Rotterdam, Netherlands; 3IJsselland Hospital, Capelle aan den IJssel, Netherlands; 4Maasstad Hospital, Rotterdam, Netherlands

Background Immune checkpoint blockade (ICB; e.g. anti-PD-1/-CTLA-4) has been proven to be clinically effective in mismatch repair deficient (dMMR) colorectal carcinoma (CRC). Yet, the majority of patients carry mismatch repair proficient (pMMR) CRC, especially those with liver metastasis, and do not respond to ICB. Here, we studied the effect of immune checkpoint stimulation via GITR targeting on human tumour-infiltrating lymphocyte (TIL) functionality in pMMR primary CRC and liver metastases (CRLM).

Methods Human TIL were isolated from freshly resected pMMR tumours of patients with primary CRC (stage 1–3) or liver metastases (table 1). GITR expression on TIL was determined using flow cytometry and compared to leukocytes isolated from blood (PBMC) and tumour-free surrounding tissues (tumour-free colon/liver, resp. TFC and TFL). Ex vivo functional assays were used to assess TIL expansion, activation and cytokine/cytotoxic mediator secretion upon CD3/CD28 bead activation and co-stimulation using an antibody-cross-linked recombinant trimeric GITR ligand (GITRL).

Results GITR was overexpressed on TIL when compared to other stimulatory immune checkpoints (4-1BB, OX40). GITR expression was enhanced on CD4+ and CD8+ TIL compared to PBMC and TFC or TFL compartments in both primary CRC and CRLM. Among CD4+ TIL, GITR was increasingly expressed on CD45RA± FoxP3- helper T (Th), CD45RA- FoxP3int activated helper T (aTh), and CD45RA- FoxP3hi activated regulatory T cells (aTreg), respectively. Within CD8+ TIL, GITR expression was higher on TOX+ PD1Hi and putatively tumour-reactive CD103+ CD39+ TIL. Impaired effector cytokine production upon ex vivo PMA/ionomycin stimulation was observed in CD4+ and CD8+ GITR-expressing TIL, hinting to functional exhaustion of the target population. However, recombinant GITRL reinvigorated ex vivo TIL responses by significantly enhancing CD4+ and CD8+ TIL numbers and proinflammatory cytokine secretion in a dose-dependent manner (figure 1). Treg depletion did not fully abrogate the stimulatory effect of GITR ligation on CD4+ and CD8+ T cell expansion, demonstrating that the stimulatory effect was partly exerted via direct targeting GITR on effector T cells. Importantly, GITR-ligation also enhanced expansion of purified CD8+CD39+ TIL. Dual treatment with GITR ligand and nivolumab (anti-PD-1) further enhanced CD8+ TIL responses compared to GITR ligand monotherapy, whereas nivolumab alone did not show any effect.

Conclusions Agonistic targeting of GITR enhances ex vivo human TIL functionality in pMMR CRC and might therefore be a promising approach for novel mono- or combinatorial immunotherapies in primary CRC and CRLM.

Acknowledgements N/A

Trial Registration N/A

Ethics Approval The study was approved by the medical ethics committee of the Erasmus Medical Center (MEC-2012-331).

Consent N/A

REFERENCE


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0588

EFFICACY OF ONCOLYTIC VACCINIA VIRUS REQUIRES INFECTION OF SUPPRESSIVE IMMUNE CELLS IN THE TUMOR MICROENVIRONMENT LEADING TO THEIR REPROGRAMMING AND DELETION

Kristin DePeaux *, Paolo Vignali, Saumendra Sarkar, Greg Delgoffe. University of Pittsburgh, Pittsburgh, PA, USA